Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) FCF Margin (2021 - 2025)

Krystal Biotech's FCF Margin history spans 4 years, with the latest figure at 78.67% for Q4 2025.

  • For Q4 2025, FCF Margin rose 2156.0% year-over-year to 78.67%; the TTM value through Dec 2025 reached 50.83%, up 981.0%, while the annual FY2025 figure was 50.83%, 981.0% up from the prior year.
  • FCF Margin for Q4 2025 was 78.67% at Krystal Biotech, up from 31.88% in the prior quarter.
  • Across five years, FCF Margin topped out at 822.32% in Q1 2021 and bottomed at 249.31% in Q3 2023.
  • The 4-year median for FCF Margin is 31.88% (2025), against an average of 81.64%.
  • The largest annual shift saw FCF Margin surged 31826bps in 2024 before it crashed -3708bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 822.32% in 2021, then tumbled by -102bps to 18.81% in 2023, then soared by 404bps to 57.11% in 2024, then surged by 38bps to 78.67% in 2025.
  • Per Business Quant, the three most recent readings for KRYS's FCF Margin are 78.67% (Q4 2025), 31.88% (Q3 2025), and 60.0% (Q2 2025).